SEC Form 4 · accession 0001179110-17-015344
Axogen, Inc. · AXGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Mark Grooms
Director
Period of report
Dec 11, 2017
Accepted (ET)
Dec 13, 2017 · 7:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000805928
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Dec 11, 2017 | S | 21,820 | $26.35 | D | 257,192 | D | |
| Common StockF4,F5 | Dec 12, 2017 | S | 16,585 | $26.34 | D | 240,607 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017 (the "Plan"). All shares pursuant to the Plan have been sold as of the last sales reported herein.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.65. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3These shares of common stock include 108,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.10 to $26.90. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5These shares of common stock include 107,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.